• Sumitomo Pharma revised its FY2026 forecasts as first-half core operating profit exceeded expectations on stronger-than-expected sales.
• First-half core operating profit reached JPY 42.1 billion, beating the July 31 forecast of JPY 30 billion.
• Revenue totaled JPY 266.5 billion against a JPY 251 billion forecast, driven by U.S. growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.